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year. Tumor size is the strongest predictor of survival. Surgery is the treatment of choice in early disease stage. In local advanced
stages, radiotherapy associated or not to chemotherapyhas beenused.Wepresent a case treatedwith external beamradiotherapy
and interstitial brachytherapy.
Material and methods. A gynecological examination performed to an 81 year old woman with vaginal bleeding and local pain
revealed a tumor mass attached to the anterior and lateral walls of the vagina and coming out the introitus. MRI and PET-
CT revealed a 6.4 cm tumor mass in the upper third of the vagina embracing the urethral septum without metastases. Biopsy
conﬁrmed malignant primary vaginal melanoma. She underwent external beam radiotherapy to the pelvis, receiving a total dose
of 46Gy, followed by interstitial brachytherapy with high dose rate (HDR) up to a 60Gy total dose.
Results. Six months later, a reduction of 3 cm in tumor size was observed on physical examination, conﬁrmed by MRI/PET-TC; 12
months clinical and repeated imaging demonstrated persistent disease in the anterior wall of the vagina on urethral meatus.
No symptom of vaginal bleeding was reported, but local pain was not controlled and patient was referred to Pain Unit. No acute
urinary or rectal toxicity were observed. The patient died 14 months later.
Conclusions. Local excision is the treatment of choice in early disease but most patients are diagnosed at advanced stage. A
combination of EBRT and interstitial brachytherapy is a reasonable treatment, but tumor size is a limitation to local control this
vagina melanoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.238
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Purpose and objective. Elevation of the SCC in early cervical cancer is associated with nodal and lymphovascular inﬁltration, and is
regarded as a marker for the need of treatment- chemo and/or radiotherapy (RT)- and poor prognosis. In this study we analyzed
SCC value as a prognostic factor before chemo-RT treatment and after completion.
Materials and methods. We followed a cohort of 236 patients from 1999 to 2011, under a weekly scheme with IV cisplatin (40mg/m2)
and concomitant RT. FIGO stage distribution was as follows: 7 (IB1), 27 (IB2), 2 (IIA), 73 (IIB), 1 (IIIA), 109 (IIIB), 17 (IVA). The SCC at
diagnosis was elevated above the cutoff point (1.5 or 2.5ng/ml) in 160 (67.8%) patients and was considered normal in 76 (32.2%).
Themeanvalues of SCC for different FIGO stageswere: IB1=1.04, IB2=5.36, IIA=0.55, IIB = 13.86, IIIA=31.80, IIIB = 20.03, IVA=34.75
(p<0.0001). The mean value amongst patients with elevated SCC, was 22.5 (r: 1.7–235, p25=4.8, p50=11.4, p75=22.4). In order to
assess SCC values at diagnosis (SCCD), we grouped patients according to their initial values: SCCD0=normal SCC, SCCD1=high
SCC -up to the value of percentile 50- (<11.4) and SCCD2=SCC≥11.4. At the end of the chemo-RT, clinical response was assessed
by physical examination (PE) and the value of SCC: PE was normal in 188 patients reﬂecting complete clinical response (CR); a
partial response (PR) over 50% was observed in 47 patients, and 1 patient remained with stable disease (SD); SCC was normal in
214 patients (SCCT0) and remained elevated in 20 (SCCT1). SCC was not performed in only 2 patients. When grouping patients
according to their combination of SCC and clinical response at the end of treatment, we obtained the following prognosis groups
(PG): PG0 (CR and normal SCC, n=173 patients), PG1 (CR and high SCC, n=14), PG2 (PR and normal SCC, n=41) and PG3 (SD and
high SCC, n=6).
Results. The mean follow-up-time was 55 months. An overall 5 year (SG5) survival using actuarial method (SG5) was found at
72.3%, with 67 deaths occurring in the following period. No statistical differences in SG5 were found between patients with
normal or elevated SCC at diagnosis, but the grouped analysis-according to SCCD- showed differences among SCCD0, SCCD1
and SCCD2 groups with values 76.2%, 86% and 57.5% respectively (p=0.0006). SG5 between SCCT1 and SCCT0 patients was 70.3%
and 25% respectively (p<0.0001), and for those with CR and PR, SG5 was 76.2% and 58.3% (p<0.0001). Finally, the SG5 in patients
PG0, PG1, PG2, PG3 was: 79.3%, 47.1%, 64.8%, and 16% respectively (p<0.0001).
Conclusions. SG5 showed to be similar amongst patients with normal and elevated SCC at diagnosis; however, an SCC value above
11.4ng/ml, showed to have worse results.
http://dx.doi.org/10.1016/j.rpor.2013.03.239
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Introduction. The treatment of locally advanced cervical carcinoma (LACC) is concomitant chemoradiation followed by brachyther-
apy or surgery as the answer reached. The objective is know our results in terms of overall survival (OS), disease-free
survival (DFS), relapse-free survival (RFS), metastasis-free survival (MFS) and toxicity (RTOG) of patients with LACC treated with
radiochemotherapy.
Material and methods. Between 1998 and June-2012, 107 patients, mean age 55±13 (25–83), were analyzed retrospectively. Distri-
bution by stages (FIGO): Ib2=10.3%, IIa = 17.8%, IIb = 31.8%, IIIa = 3.7% IIIb = 29.9% and IVA=6.6%. Histologically, 88% epidermoid
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carcinoma and 11.2% adenocarcinoma. Degree of differentiation: 37.3% G1–G2 and 37.4% G3. 25.2% Gx. External radiation ther-
apy was administered on pelvic±para-aortic, with parametrial boost if indicated (18.7%). Mean dose 46.7Gy, 1.8Gy/d (34–75). All
patients received chemotherapy with weekly CDDP, 40mg/m2. After treatment, 52.3% achieved complete response while 46.7%
were partial responses. 64 patients (59.8%) were salvaged surgically and 54 (84.4%) receiving brachytherapy later. 30 patients
continued with brachytherapy and 13 with external radiotherapy. Mean and standard deviation for quantitative variables and
absolute frequency and percentage for qualitative variables were obtained. The Kaplan–Meier method was used to estimate
patient survival.
Results. The median duration of follow-up was 39.5 months (7.2–178.6). OS at 3 and 5 years was 78.4% and 64.7% respectively. DFS
in the same periods was 60% and 55.6%. 22.4% patients had local disease recurrence and 25.2% metastases (nodal o visceral). RFS
at 3 and 5 years was 78.8% and 75.1% respectively while MFS was 72.3% and 68.8%. Acute toxicity: urinary, 22.5% G1 and 2.8% G2.
Gastrointestinal: 20.6% G1, 11.2% G2 and 0.9% G3. Late toxicity: urinary, 7.5% G1. Gastrointestinal: 1.8% G1–2.
Conclusion. Our results are similar to other historical series (Claire Vale et al., Meta-analysis). Radiochemotherapy for locally
advances cervical cancer providing good results in DFS and OS with good tolerance and low morbidity.
http://dx.doi.org/10.1016/j.rpor.2013.03.240
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Introduction. Radiation induced SIF is a fracture that results from normal stress applied to weakened bone due to radiotherapy (RT)
in pelvic malignancies. Sacroiliac joint is the most common involved site. Studies have shown a high variability about incidence
(range 3–89%). Latency since radiation to develop a fracture is known to occur between 1 and 190 months. Magnetic Resonance
Imaging (MRI) is currently the method of choice to evaluate SIF due to high sensitiveness. The aim of this article is to describe
SIF risk factors after pelvic RT and the usefulness of MRI technique.
Methods and materials. Data from 13 patients (all females) with pelvic cancer diagnosed as having radiation induced SIF were
reviewed retrospectively. The malignancies included cervical (10), endometrial (1) and rectal cancer (2). Median dose delivered
to whole pelvis was 54Gy (range 44–68). Risk factors including age, postmenopausal stage, diabetes, concurrent chemotherapy,
arterial hypertension and current smoking were recorded. MRI was used to diagnose SIF following RT due to its sensitiveness to
mild changes in bone marrow signal.
Results. Median age of 13 patients was 57 years (range 46–87). Predisposing factors included menopause (13/13), concomitant
chemotherapy (11/13), brachytherapy boost (11/13), current smoking (5/13), arterial hypertension (2/13), diabetes (1/13) and osteo-
porosis (1/13). Most common symptoms were diffuse low back pain radiating to the pelvis and sacral radiculopathy (up to 70%).
The radiological change most frequently seen in SIF was marrow edema. MRI ﬁndings presented as areas of high signal intensity
(SI) on T2 and STIR sequences and low SI on T1.
Conclusions. Pelvic radiotherapy can lead to sacral insufﬁciency fracturesmore likelywhenother comorbidities factors are present.
MRI has became the best imaging method to evaluate SIF in post-treated pelvic malignancies
http://dx.doi.org/10.1016/j.rpor.2013.03.241
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Aim. To evaluate the feasibility of radical radiotherapy after laparoscopic para-aortic lymphadenectomy for staging cervical
carcinoma (CC) patients stages IB-IIIB.
Methods. From March 2009 to December 2012, from 107 patients with CC treated, 62 underwent laparoscopic para-aortic lym-
phadenectomy for staging ﬁrst. Radiotherapy treatment was tailored according the results. External radiation therapy with
concurrent cisplatin (40mg/m2/sem) on cervical tumor and lymph nodes with concomitant para-aortic irradiation in nodes
positive patients, and high dose rate (HDR) brachytherapy boost.
Results. Mean age was 48.05(range, 28–69 years). Average of 13.36 lymph nodes were removed (range 2–34). Ten (16.1%) of 62
patients had metastatic disease in para-aortic nodes and received para-aortic treatment. Mean dose to pelvic volume was 49.5Gy
and 45.24Gy to para-aortic volume. HDR brachytherapy (intrauterine tandem and vaginal colpostates) was delivered in 4–5
fractions of 550–700 cGy. Both radiation procedures were planned with 3D CT guided dosimetry and MRI was used for image-
guided brachytherapy in the last patients.With amean follow-up time of 19months (range 1–43months) actuarial overall survival
